Bruce Salzberg, MD
Gastroenterology · Suwanee, GANPI 1376528943
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $201,956 of the $275,253 with a category attached, or 73.4%. 27 manufacturers reported payments, led by Johnson & Johnson at 40.8% of the total. Reporting peaked in 2019 at $87,089 and has fallen 53.3% since, to $40,647 in 2025. Among gastroenterology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 625 payments — averaging $440.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$112K
- Janssen Scientific Affairs, LLC$106K
- Takeda Pharmaceuticals U.S.A., Inc.$20K
- E.r. Squibb & Sons, L.L.C.$15K
- Pfizer$10K
- AbbVie$6K
- plus $5K from 21 others
Across 298 payments — averaging $3994.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$425K
- Janssen Research & Development, LLC$366K
- Gilead$129K
- Pfizer$127K
- E.r. Squibb & Sons, L.L.C.$82K
- Takeda Pharmaceuticals U.S.A., Inc.$23K
- plus $38K from 4 others
What the payments were for
- Consulting fees$23,1928%
- Speaking & faculty fees$201,95673%
- Travel & lodging$40,56015%
- Food & beverage$9,2943%
- Education$1040%
- Gifts$1470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 162 | $112,402 |
| Janssen Scientific Affairs, LLC | 88 | $105,542 |
| Takeda Pharmaceuticals U.S.A., Inc. | 50 | $19,968 |
| E.r. Squibb & Sons, L.L.C. | 9 | $15,473 |
| Pfizer | 45 | $10,426 |
| AbbVie(2 entities) | 154 | $6,158 |
| Bristol Myers Squibb | 51 | $4,145 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 25 | $234 |
| Regeneron Healthcare Solutions, Inc. | 7 | $171 |
| Braintree Laboratories, Inc. | 2 | $147 |
| Daiichi Sankyo Inc. | 5 | $71 |
| Sanofi | 1 | $70 |
| Lilly USA, LLC | 3 | $58 |
| Medtronic | 1 | $46 |
| Merck | 3 | $42 |
| Ferring Pharmaceuticals Inc. | 3 | $38 |
| Olympus America Inc. | 2 | $34 |
| Alfasigma USA, Inc. | 2 | $33 |
| UCB, Inc. | 2 | $31 |
| QOL Medical, LLC | 2 | $30 |
| Boston Scientific | 2 | $28 |
| Mauna Kea Technologies, Inc. | 1 | $27 |
| Gilead | 1 | $25 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Amgen | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$275,253 in reported general payments places this provider in the 95th percentile of 492 gastroenterology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 46 | $1,248,062 |
| SimponiGolimumab | 13 | $95,497 |
| LinzessLinaclotide | 31 | $27,829 |
| DexilantDexlansoprazole | 12 | $3,609 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 19 | $3,081 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 11 | $1,931 |
| Pantoprazole Sodium | 177 | $1,832 |
| Budesonide EcBudesonide | 12 | $732 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 11 | $690 |
| Ondansetron Hcl | 19 | $554 |
| Promethazine Hcl | 12 | $547 |
| Sucralfate | 17 | $380 |
| Omeprazole | 14 | $289 |
| Ciprofloxacin Hcl | 24 | $281 |
| Prednisone | 18 | $215 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Simponi | $112,402 | $1,343,55959 claims |
| AbbVieLinzess | $6,158 | $27,82931 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $19,968 | $3,60912 claims |
| Braintree Laboratories, Inc.Sutab | $147 | $3,08119 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $38 | $1,93111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 492 gastroenterology providers in Georgia.
Other gastroenterology in Suwanee
- Patricia Sanchez FerminSuwanee$13K
- Nitin GuptaAtlanta$1.1M
- Cynthia RudertAtlanta$720K
- Douglas WolfAtlanta$668K
- Kavita KongaraAtlanta$492K
- Girish AnandAtlanta$425K
- Satish RaoAugusta$335K
- Roshan ShresthaAtlanta$317K
- Hetal KarsanAtlanta$314K
- Aja McCutchenWinder$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.